

New Standard of Care for Aortic Arch Disease including Aneurysms and Dissections Is Now Possible with NEXUS™

NEXUS™ Stent Graft System is designed to transform treatment of life threatening Aortic Arch Disease from high-risk open surgery into a minimally invasive procedure.

■ **SIGNIFICANT UNMET CLINICAL NEED FOR TREATING AORTIC ARCH DISEASE.** Aortic Arch Disease includes (1) aortic aneurysms, and (2) aortic dissections, which occur suddenly and usually without warning with symptoms of severe chest pain, loss of consciousness and paralysis similar to a stroke. Unfortunately, many Aortic Arch aneurysms and dissections are either not diagnosed or misdiagnosed in emergency situations. 120,000 patients suffer thoracic aortic arch disease annually in the USA and Europe, but only 25% are diagnosed or treated.


■ **CLINICALLY ESTABLISHED PRODUCT EXPECTED TO BE FIRST TO MARKET.** Endospan is in the midst of seeking CE marking for NEXUS. Published data in the peer-reviewed *Journal of Thoracic Cardiovascular Surgery* demonstrated that NEXUS reduced mortality and the incidence of stroke at 30 days versus the current standard of care (Hybrid Repair) by more than 50% among 28 patients implanted with NEXUS at nine different clinical sites.

■ **STATE-OF-THE-ART ENDOVASCULAR REPAIR TECHNOLOGY.** NEXUS transforms a complex surgical aortic arch repair into a standard endovascular procedure. NEXUS is designed for enhanced intra-procedural and long-term stability attributable to its proprietary geometrical design, which reduces arch manipulation and, hence, stroke risks. NEXUS also is designed to reduce complications and post-op recovery time. Above all, NEXUS is designed to be beneficial to the vast number of patients for whom there is currently no minimally invasive Aortic Arch Disease treatment alternative.

■ **NEXUS™ IS INDICATED FOR ALL AORTIC ARCH PATHOLOGIES.** The NEXUS Stent Graft System is the first branched endovascular system to treat Aortic Arch Disease: a greatly underserved patient population diagnosed with a dilative lesion in, or near, the aortic arch. Minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), but Thoracic Aortic Arch (TAA) repair patients with aneurysms or dissections have not been as fortunate, with little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.

Note: The NEXUS™ Stent Graft System is approved for investigational use, and the CE mark registration process is underway in Europe.

What the experts are saying:




Ross Milner, MD
Director, Center for Aortic Diseases
University of Chicago Medicine

"An endovascular approach to widen or repair narrowed arteries in the aortic arch would be a significant medical advance."



Thomas Lindsay, MD
Chief, Vascular Surgery
Toronto General Hospital

"NEXUS gives vascular surgeons a minimally invasive alternative to offer patients compared with open heart surgery to repair their life threatening aortic arch disease."



NEXUS (above, left) is the first off-the-shelf, branched endovascular repair system to treat Aortic Arch Disease.